Chemo-radiotherapy in non-small cell lung cancer: The role of gemcitabine

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Trodella, L ^a   D'Angelillo, R M ^a   Ramella, S ^a   Cellini, F ^a   Ciresa, M ^a   Cesario, A ^b,c   Granone, P ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; FLUOROPYRIMIDINE DERIVATIVE; GEMCITABINE; NAVELBINE; PACLITAXEL; THYMIDINE DERIVATIVE;

ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG FATALITY; DRUG MECHANISM; ESOPHAGITIS; GRANULOCYTOPENIA; HEMATOLOGIC DISEASE; HUMAN; IN VITRO STUDY; LEUKOPENIA; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RADIOSENSITIZATION; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; RADIATION-SENSITIZING AGENTS;

EID: 33745613825     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj950     Document Type: Article

References (26)

1. Hertel LW, Boder GB, Kroin JS et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417-4422.
2. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-b-D-arabinofuranosylcytosine. Cancer Res 1988; 48: 4024-4031.
3. Heinemann V, Xu YZ, Chubb S et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990; 38: 567-572.
4. Heinemann V, Xu YZ, Chubb S et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation. Cancer Res 1992; 52: 533-539.
5. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994; 54: 3218-3223.
6. Lawrence TS, Chang EY, Hahn TM, Shewach DS. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (gemcitabine). Clin Cancer Res 1997; 3: 777-782.
7. Abbruzzese JL, Grunewald R, Weeks EA et al. A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-498.
8. Lawrence TS, Davis MA, Normolle DP. Effect of bromodeoxyuridine on radiation-induced DNA damage and repair based on DNA fragment size using pulsed-field gel electrophoresis. Radiat Res 1995; 144: 282-287.
9. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-6117.
10. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2′2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 1996; 34: 867-872.
11. Ostruszka LJ, Shewach DS. The role of cell cycle progression in radiosensitization by 2′2′-difluoro-2′-deoxycytidine. Cancer Res 2000; 60: 6080-6088.
12. Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber KJ. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 1998; 41: 875-882.
13. Lawrence TS, Davis MA, Hough A, Rehemtulla A. The role of apoptosis in 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine)-mediated radiosensitization. Clin Cancer Res 2001; 7: 314-319.
14. Scalliet P, Goor C, Galdermans D et al. Gemzar (Gemcitabine) with thoracic radiotherapy - A phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998;.17: (Abstr #1923).
15. Vokes EE, Herndon JE 2nd, Crawford J et al. Randomized Phase II Study Of Cisplatin With Gemcitabine Or Paclitaxel Or Vinorelbine As Induction Chemotherapy Followed By Concomitant Chemoradiotherapy For Stage IIIB Non-Small-Cell Lung Cancer: Cancer And Leukemia Group B Study 9431. J Clin Oncol 2002 Oct 15; 20(20): 4191-4198.
16. Blackstock AW, Bernard SA, Richards F et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced NSCLC. Int J Radiat Biol 2001; 51: 1281-1289.
17. Trodella L, Granone P, Valente S et al. Phase I Trial of Weekly Gemcitabine and Concurrent Radiotherapy in Patients With Inoperable Non-Small-Cell Lung. Cancer J Clin Oncol 2002; 20: 804-810.
18. Galetta D, Cesario A, Margaritora S et al. Multimodality treatment of unresectable stage III non-small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy. J Thorac Cardiovasc Surg. 2006; 131: 314-321.
19. Graham MV, Purdy JA, Emami B et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999; 45(2): 323-9.
20. Hernando ML, Marks LB, Bentel GC et al. Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001 Nov 1; 51(3): 650-9.
21. Emami B, Mirkovic N, Scott C et al. The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: An analysis of RTOG data. Lung Cancer 2003; 41: 207-214.
22. Rosenzweig KE, Sim SE, Mychalczak B et al. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50: 681-5.
23. Bradley JD, Wahab S, Lockett MA et al. Elective nodal failures are uncommon in medically inoperable patients with Stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int J Radiat Oncol Biol Phys 2003; 56: 342-347.
24. Hayman JA, Martel MK, Ten Haken RK et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial. J Clin Oncol 2001; 19: 127-136.
25. Bradley JD, Ieumwananonthachai N, Purdy JA et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2002; 52: 49-57.
26. ICRU 62. Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50) (1999).